Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S. Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, A. Tufman, M. Lambrecht, N. Andratschke, A. C. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R. A. Stahel, J. VansteenkisteD. De Ruysscher*
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial'. Together they form a unique fingerprint.